ijcr@oajrc.org

国际临床研究杂志

International Journal of Clinical Research

您当前位置:首页 > 精选文章

International Journal of Clinical Research. 2022; 6: (9) ; 10.12208/j.ijcr.20220429 .

Efficacy observation of adalimumab in the treatment of severe plaque psoriasis
阿达木单抗治疗重度斑块型银屑病疗效观察

作者: 黄少辉*, 李渊, 李淑婧, 何丽

武警甘肃省总队医院 甘肃兰州

*通讯作者: 黄少辉,单位:武警甘肃省总队医院 甘肃兰州;

引用本文: 黄少辉, 李渊, 李淑婧, 何丽 阿达木单抗治疗重度斑块型银屑病疗效观察[J]. 国际临床研究杂志, 2022; 6: (9) : 4-6.
Published: 2022/11/23 18:20:14

摘要

目的 探讨阿达木单抗治疗重度斑块型银屑病的疗效。方法 根据本院2021-04至2022-04这一年中,将收治的重度斑块型银屑病患者,随机抽选76例进行研究,并以数字抽签法对患者进行分组治疗,对照组患者有38例,接受常规西药治疗,另外的观察组,同样有38例,应用阿达木单抗治疗,对2组患者治疗的临床疗效、皮肤状况及不良反应等指标展开对比与分析。结果 通过评估2组患者的不良反应,其观察组患者出现的发热、上呼吸感染及皮肤干燥发生率更低于对照组患者,(P<0.05)。结论 对于重度斑块型银屑病患者的治疗,临床应用阿达木单抗的疗效确切且安全性高,利于改善患者的皮损状况,促进患者早日康复,值得推广。

关键词: 阿达木单抗;重度斑块银屑病;疗效

Abstract

Objective: To investigate the efficacy of adalimumab in the treatment of severe plaque psoriasis.
Methods: According to the year 2021-04 to 2022-04, 76 patients with severe plaque psoriasis who were admitted to our hospital were randomly selected for research, and the patients were divided into groups by digital lottery method, and the control group There were 38 patients who received conventional western medicine treatment, and 38 patients in the other observation group were also treated with adalimumab. The clinical efficacy, skin conditions and adverse reactions of the two groups of patients were compared and analyzed.
Results: By evaluating the adverse reactions of the two groups of patients, the incidence of fever, upper respiratory infection and dry skin in the observation group was lower than that in the control group (P<0.05).
Conclusion  : For the treatment of patients with severe plaque psoriasis, the clinical application of adalimumab has definite curative effect and high safety.

Key words: Adalimumab; Severe Plaque Psoriasis; Efficacy

参考文献 References

[1] 刘婷,樊晓红,曾跃平,秦岩,艾三喜,李雪梅. 阿达木单抗致银屑病患者IgA肾病和红皮病[J]. 药物不良反应杂志,2022,24(06):332-334.

[2] 马云霞,胡凤侠,张祥月,康晓静. 阿达木单抗治疗儿童中重度斑块型银屑病11例临床疗效及安全性观察[J]. 中国皮肤性病学杂志,2022,36(06):675-679.

[3] 冯新颖,李斌,陈换飞,朱韶峰. 治疗中至重度斑块型银屑病新药:Risankizumab[J]. 中国现代应用药学,2021, 38(20): 2621-2624.

[4] 王宥霖,王睿,赵振凯,孙杰,张媛,汤自洁,张菡,舒心,李承新. 阿达木单抗治疗斑块型银屑病疗效及代谢综合征对疗效的影响[J]. 中国麻风皮肤病杂志,2021,37(12): 755-758.

[5] 张丽,吴忠孝,沈燕娜,毛凤,任有刚,杨谋哲,吴昊. 阿达木单抗长疗程治疗中重度银屑病的临床疗效及安全性[J]. 现代实用医学,2021,33(05):666-668.

[6] 谢倩,邓彩弟,关立昕. 肿瘤坏死因子-α抑制剂治疗中重度斑块型银屑病的疗效观察[J]. 黑龙江医药,2020, 33(05): 1108-1110.

[7] 刘鸿伟,胡雪英,雷东春,张守民. 阿达木单抗治疗重度斑块状银屑病的临床观察[J]. 中华皮肤科杂志,2020, 53(09): 744-746.

[8] 屠远辉,吴涛,刘爱民,张步鑫. 修美乐联合麻防犀角地黄汤对中重度斑块型银屑病的临床疗效及相关免疫炎症指标的影响[J]. 中华中医药学刊,2021,39(05):57-59.

[9] NINA Bhochhibhoya,张莉娜,郑捷,李霞. 阿达木单抗与乌司奴单抗治疗中重度斑块型银屑病的疗效及复发的比较[J]. 中国皮肤性病学杂志,2019,33(12):1376-1382.

[10] 周欣,毕新岭,顾军. 维生素D受体基因CDX2多态性与阿达木单抗治疗中重度斑块型银屑病疗效相关性研究[J]. 中国中西医结合皮肤性病学杂志,2015,14(05): 273-275.

[11] 易多奇,胡晓舒,毛振坤. 阿达木单抗治疗重度银屑病的疗效观察[J]. 皮肤病与性病,2020,42(01):3-4.